BOSTON SCIENTIFIC CORP (BSX.DE) Fundamental Analysis & Valuation

FRA:BSX • US1011371077

Current stock price

48.62 EUR
+0.18 (+0.38%)
Last:

This BSX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. BSX.DE Profitability Analysis

1.1 Basic Checks

  • BSX had positive earnings in the past year.
  • BSX had a positive operating cash flow in the past year.
  • In the past 5 years BSX has always been profitable.
  • In the past 5 years BSX always reported a positive cash flow from operatings.
BSX.DE Yearly Net Income VS EBIT VS OCF VS FCFBSX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • With a decent Return On Assets value of 6.64%, BSX is doing good in the industry, outperforming 77.59% of the companies in the same industry.
  • The Return On Equity of BSX (11.96%) is better than 81.03% of its industry peers.
  • The Return On Invested Capital of BSX (8.70%) is better than 75.86% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BSX is in line with the industry average of 9.41%.
  • The 3 year average ROIC (7.70%) for BSX is below the current ROIC(8.70%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.64%
ROE 11.96%
ROIC 8.7%
ROA(3y)5.27%
ROA(5y)4.17%
ROE(3y)9.54%
ROE(5y)7.64%
ROIC(3y)7.7%
ROIC(5y)7.08%
BSX.DE Yearly ROA, ROE, ROICBSX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

1.3 Margins

  • The Profit Margin of BSX (14.44%) is better than 87.93% of its industry peers.
  • In the last couple of years the Profit Margin of BSX has grown nicely.
  • BSX has a better Operating Margin (19.92%) than 82.76% of its industry peers.
  • BSX's Operating Margin has improved in the last couple of years.
  • The Gross Margin of BSX (69.01%) is better than 81.03% of its industry peers.
  • BSX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 19.92%
PM (TTM) 14.44%
GM 69.01%
OM growth 3Y6.86%
OM growth 5Y16.97%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y1.13%
BSX.DE Yearly Profit, Operating, Gross MarginsBSX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BSX.DE Health Analysis

2.1 Basic Checks

  • BSX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for BSX has been increased compared to 1 year ago.
  • Compared to 5 years ago, BSX has more shares outstanding
  • Compared to 1 year ago, BSX has an improved debt to assets ratio.
BSX.DE Yearly Shares OutstandingBSX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B
BSX.DE Yearly Total Debt VS Total AssetsBSX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • An Altman-Z score of 3.63 indicates that BSX is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of BSX (3.63) is better than 72.41% of its industry peers.
  • BSX has a debt to FCF ratio of 3.13. This is a good value and a sign of high solvency as BSX would need 3.13 years to pay back of all of its debts.
  • BSX's Debt to FCF ratio of 3.13 is fine compared to the rest of the industry. BSX outperforms 74.14% of its industry peers.
  • BSX has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
  • BSX has a Debt to Equity ratio (0.46) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 3.13
Altman-Z 3.63
ROIC/WACC1.06
WACC8.17%
BSX.DE Yearly LT Debt VS Equity VS FCFBSX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • BSX has a Current Ratio of 1.62. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
  • BSX has a Current ratio of 1.62. This is comparable to the rest of the industry: BSX outperforms 46.55% of its industry peers.
  • BSX has a Quick Ratio of 1.08. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of BSX (1.08) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.08
BSX.DE Yearly Current Assets VS Current LiabilitesBSX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. BSX.DE Growth Analysis

3.1 Past

  • BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.81%, which is quite good.
  • BSX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 26.01% yearly.
  • BSX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.44%.
  • The Revenue has been growing by 15.16% on average over the past years. This is quite good.
EPS 1Y (TTM)14.81%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%6.67%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%11.58%

3.2 Future

  • BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.09% yearly.
  • Based on estimates for the next years, BSX will show a quite strong growth in Revenue. The Revenue will grow by 10.44% on average per year.
EPS Next Y14.33%
EPS Next 2Y13.76%
EPS Next 3Y13.36%
EPS Next 5Y13.09%
Revenue Next Year10.74%
Revenue Next 2Y10.45%
Revenue Next 3Y10.28%
Revenue Next 5Y10.44%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BSX.DE Yearly Revenue VS EstimatesBSX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B 40B
BSX.DE Yearly EPS VS EstimatesBSX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. BSX.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 18.35, which indicates a rather expensive current valuation of BSX.
  • Based on the Price/Earnings ratio, BSX is valued a bit cheaper than 79.31% of the companies in the same industry.
  • BSX is valuated rather cheaply when we compare the Price/Earnings ratio to 26.77, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 14.42, which indicates a correct valuation of BSX.
  • 68.97% of the companies in the same industry are more expensive than BSX, based on the Price/Forward Earnings ratio.
  • BSX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.75.
Industry RankSector Rank
PE 18.35
Fwd PE 14.42
BSX.DE Price Earnings VS Forward Price EarningsBSX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • BSX's Enterprise Value to EBITDA ratio is in line with the industry average.
  • BSX's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 23.12
EV/EBITDA 17.46
BSX.DE Per share dataBSX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • BSX has an outstanding profitability rating, which may justify a higher PE ratio.
  • BSX's earnings are expected to grow with 13.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.28
PEG (5Y)0.71
EPS Next 2Y13.76%
EPS Next 3Y13.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BSX.DE Dividend Analysis

5.1 Amount

  • No dividends for BSX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BSX.DE Fundamentals: All Metrics, Ratios and Statistics

BOSTON SCIENTIFIC CORP

FRA:BSX (4/30/2026, 7:00:00 PM)

48.62

+0.18 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength11.18
Industry Growth60.87
Earnings (Last)04-22
Earnings (Next)07-21
Inst Owners94.54%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap72.26B
Revenue(TTM)20.61B
Net Income(TTM)2.90B
Analysts84.88
Price Target86.84 (78.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.84%
Min EPS beat(2)1.62%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)4.68%
Min EPS beat(4)1.62%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)5.56%
EPS beat(12)12
Avg EPS beat(12)5.7%
EPS beat(16)15
Avg EPS beat(16)4.38%
Revenue beat(2)1
Avg Revenue beat(2)0.04%
Min Revenue beat(2)-0.88%
Max Revenue beat(2)0.96%
Revenue beat(4)3
Avg Revenue beat(4)0.87%
Min Revenue beat(4)-0.88%
Max Revenue beat(4)2.43%
Revenue beat(8)7
Avg Revenue beat(8)1.73%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.59%
PT rev (1m)-4.62%
PT rev (3m)-20.29%
EPS NQ rev (1m)-0.17%
EPS NQ rev (3m)-0.45%
EPS NY rev (1m)-0.28%
EPS NY rev (3m)-0.44%
Revenue NQ rev (1m)-0.06%
Revenue NQ rev (3m)-0.46%
Revenue NY rev (1m)-0.16%
Revenue NY rev (3m)-0.62%
Valuation
Industry RankSector Rank
PE 18.35
Fwd PE 14.42
P/S 4.21
P/FCF 23.12
P/OCF 18.66
P/B 3.49
P/tB N/A
EV/EBITDA 17.46
EPS(TTM)2.65
EY5.45%
EPS(NY)3.37
Fwd EY6.94%
FCF(TTM)2.1
FCFY4.32%
OCF(TTM)2.61
OCFY5.36%
SpS11.54
BVpS13.93
TBVpS-0.61
PEG (NY)1.28
PEG (5Y)0.71
Graham Number28.8189 (-40.73%)
Profitability
Industry RankSector Rank
ROA 6.64%
ROE 11.96%
ROCE 10.46%
ROIC 8.7%
ROICexc 9.17%
ROICexgc 30.32%
OM 19.92%
PM (TTM) 14.44%
GM 69.01%
FCFM 18.22%
ROA(3y)5.27%
ROA(5y)4.17%
ROE(3y)9.54%
ROE(5y)7.64%
ROIC(3y)7.7%
ROIC(5y)7.08%
ROICexc(3y)7.95%
ROICexc(5y)7.36%
ROICexgc(3y)27.25%
ROICexgc(5y)24.65%
ROCE(3y)9.26%
ROCE(5y)8.51%
ROICexgc growth 3Y16.23%
ROICexgc growth 5Y30.87%
ROICexc growth 3Y13.89%
ROICexc growth 5Y25.4%
OM growth 3Y6.86%
OM growth 5Y16.97%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y1.13%
F-Score7
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 3.13
Debt/EBITDA 2.08
Cap/Depr 64.04%
Cap/Sales 4.36%
Interest Coverage 12.54
Cash Conversion 84.48%
Profit Quality 126.23%
Current Ratio 1.62
Quick Ratio 1.08
Altman-Z 3.63
F-Score7
WACC8.17%
ROIC/WACC1.06
Cap/Depr(3y)61.91%
Cap/Depr(5y)57.64%
Cap/Sales(3y)4.69%
Cap/Sales(5y)4.67%
Profit Quality(3y)127.68%
Profit Quality(5y)132.57%
High Growth Momentum
Growth
EPS 1Y (TTM)14.81%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%6.67%
EPS Next Y14.33%
EPS Next 2Y13.76%
EPS Next 3Y13.36%
EPS Next 5Y13.09%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%11.58%
Revenue Next Year10.74%
Revenue Next 2Y10.45%
Revenue Next 3Y10.28%
Revenue Next 5Y10.44%
EBIT growth 1Y30.81%
EBIT growth 3Y24.54%
EBIT growth 5Y34.7%
EBIT Next Year24.39%
EBIT Next 3Y16.29%
EBIT Next 5Y14.16%
FCF growth 1Y38.35%
FCF growth 3Y57.4%
FCF growth 5Y29.98%
OCF growth 1Y32.03%
OCF growth 3Y43.76%
OCF growth 5Y24.63%

BOSTON SCIENTIFIC CORP / BSX.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to BSX.DE.


What is the valuation status for BSX stock?

ChartMill assigns a valuation rating of 5 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for BOSTON SCIENTIFIC CORP?

BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for BSX stock?

The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 18.35 and the Price/Book (PB) ratio is 3.49.


Can you provide the dividend sustainability for BSX stock?

The dividend rating of BOSTON SCIENTIFIC CORP (BSX.DE) is 0 / 10 and the dividend payout ratio is 0%.